Please note that IPD sharing statement and summary results sections will be added to the ANZCTR form in the coming weeks in order to comply with the updated WHO Trial Registration Data Set.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01308567




Trial ID
NCT01308567
Ethics application status
Date submitted
3/03/2011
Date registered
3/03/2011
Date last updated
11/04/2018

Titles & IDs
Public title
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Scientific title
Randomized, Open Label, Multi-Center Study Comparing Cabazitaxel at 25 mg/m^2 and at 20 mg/m^2 in Combination With Prednisone Every 3 Weeks to Docetaxel in Combination With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Not Pretreated With Chemotherapy
Secondary ID [1] 0 0
2010-022064-12
Secondary ID [2] 0 0
EFC11784
Universal Trial Number (UTN)
Trial acronym
FIRSTANA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Prostate Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Cabazitaxel (XRP6258)
Treatment: Drugs - Docetaxel (XRP6976)
Treatment: Drugs - Prednisone

Experimental: Cabazitaxel 25 mg/m^2 - Cabazitaxel 25 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until disease progression (DP), unacceptable toxicity or participant's refusal.

Experimental: Cabazitaxel 20 mg/m^2 - Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.

Active Comparator: Docetaxel 75 mg/m^2 - Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.


Treatment: Drugs: Cabazitaxel (XRP6258)
Pharmaceutical form: Solution for injection; Route of administration: Intravenous

Treatment: Drugs: Docetaxel (XRP6976)
Pharmaceutical form: Solution for injection'; Route of administration: Intravenous

Treatment: Drugs: Prednisone
Pharmaceutical form: Tablet; Route of administration: Oral

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival (OS) - OS was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date participant was known to be alive, or at the cut-off date if the participant's last contact was after the cut-off date. The study cut-off date for the final analysis of OS was the date when the 774th death had been observed. Analysis was performed by Kaplan-Meier method.
Timepoint [1] 0 0
Baseline up to death or study cut-off date, whichever was earlier (maximum duration: 51 months)
Secondary outcome [1] 0 0
Progression Free Survival (PFS) - PFS: time interval between date of randomization to date of first occurrence of any of following events: tumor progression according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1; Prostate Specific Antigen (PSA) progression; pain progression or death due to any cause. Analysis was performed by Kaplan-Meier method.
Timepoint [1] 0 0
Baseline up to tumor progression, PSA progression, pain progression or death (maximum duration: 51 months)
Secondary outcome [2] 0 0
Time to Tumor Progression Free Survival - Time to tumor progression free survival was defined as the time interval between randomization and the date of first occurrence of tumor progression (assessed using RECIST version 1.1) or death, whichever was earlier. Analysis was performed by Kaplan-Meier method.
Timepoint [2] 0 0
Baseline up to tumor progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)
Secondary outcome [3] 0 0
Percentage of Participants With Overall Objective Tumor Response - Overall objective tumor response was defined as having a partial response (PR) or complete response (CR) according to the RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Timepoint [3] 0 0
Baseline up to DP or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)
Secondary outcome [4] 0 0
Time to Prostate Serum Antigen Progression Free Survival (PSA-PFS) - Time to PSA-PFS: time interval between date of randomization & first occurrence of PSA progression/ death, whichever was earlier. PSA progression:1) In PSA responders(=50% decline from baseline PSA of =10 ng/mL):increase of =25%(at least 2 ng/mL)over nadir value, confirmed by second PSA value at least 3 weeks later;2)In PSA non-responders(not achieved =50% decline from baseline PSA =10 ng/mL):increase of =25% (at least 2 ng/mL) over baseline value, confirmed by second PSA value at least 3 weeks later;3)In participants not eligible for PSA response(baseline PSA <10 ng/mL):(a)in participants with baseline PSA>0 ng/mL&<10 ng/mL: increase in PSA by 25% (at least 2 ng/mL) above baseline level, confirmed by second PSA value at least 3weeks apart;(b)in participants with baseline value=0ng/mL: a post baseline PSA value =2ng/mL.Early rise in PSA only indicated progression if it was associated with another sign of DP or if it continued beyond 12 weeks. Analysis performed by Kaplan-Meier method.
Timepoint [4] 0 0
Baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier ((maximum duration: 51 months)
Secondary outcome [5] 0 0
Percentage of Participants With PSA Response - PSA response was defined as =50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later in participants with baseline PSA value =10 ng/mL.
Timepoint [5] 0 0
Baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)
Secondary outcome [6] 0 0
Time to Pain Progression Free Survival (Pain PFS) - Time to pain PFS was defined as the time interval between date of randomization and the date of the first occurrence of pain progression or death, whichever was earlier. Pain progression was defined as an increase of =1 point in the median present pain intensity (PPI) score from the nadir confirmed by a second assessment at least 3 weeks later or =25 % increase in the mean analgesic score from baseline, due to cancer related pain confirmed by a second assessment at least 3 weeks later or requirement for local palliative radiotherapy. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points. Analysis was performed by Kaplan-Meier method.
Timepoint [6] 0 0
Baseline until disease progression, death or study cut-off date (maximum duration: 51 months)
Secondary outcome [7] 0 0
Percentage of Participants With Pain Response - Pain response was defined as either a =2-point decrease from baseline median PPI score without increase in analgesic score, or a =50% decrease in analgesic use from baseline mean analgesic score (only in participants with baseline mean analgesic score=10) without increase in the pain. Either criterion was maintained for 2 consecutive evaluations at least 3 weeks apart. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points.
Timepoint [7] 0 0
Baseline until pain progression, death or study cut-off date (maximum duration: 51 months)
Secondary outcome [8] 0 0
Skeletal Related Events (SRE) Free Survival - SRE free survival was defined as the time interval between the date of randomization and the date of the occurrence of the first event defining a SRE or death due to any cause, whichever was earlier. SRE were assessed by clinical evaluation. Occurrence of SRE was defined as: pathological fracture(s) and/or spinal cord compression; need for bone irradiation, including radioisotopes or bone surgery; and change of antineoplastic therapy (including introduction of bisphosphonates or denosumab in the setting of increased pain) to treat bone pain. Analysis was performed by Kaplan-Meier method.
Timepoint [8] 0 0
Baseline until occurrence of first SRE or death (maximum duration: 51 months)
Secondary outcome [9] 0 0
Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score as a Measure of Health Related Quality of Life (HRQoL) - FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to156 with higher score indicated better quality of life with fewer symptoms.
Timepoint [9] 0 0
Baseline, Day 1 of each cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 (each cycle 21-day); post-treatment follow up 1, 2, 3, 4, 5, 6 (each up to 12 weeks)
Secondary outcome [10] 0 0
Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P):Trial Outcome Index (TOI) as a Measure of HRQoL - FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). Physical well being, functional well being, and prostate-specific concerns sub-scales of the FACT-P questionnaire were combined to calculate TOI. Total TOI score ranges from 0 to 104, with higher scores representing a better quality of life with fewer symptoms.
Timepoint [10] 0 0
Baseline, Day 1 of each cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 (each cycle 21-day); post-treatment follow up 1, 2, 3, 4, 5, 6 (each up to 12 weeks)

Eligibility
Key inclusion criteria
Inclusion criteria :

- I 01. Histologically- or cytologically-confirmed prostate adenocarcinoma.

- I 02. Metastatic disease.

- I 03. Progressive disease while receiving hormonal therapy or after surgical
castration.

- I 04. Effective castration (serum testosterone levels =0.50 ng/mL) by orchiectomy
and/or luteinizing hormone-releasing hormone (LHRH) agonists or antagonist with or
without anti-androgens.
Minimum age
18 Years
Maximum age
No limit
Gender
Males
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

- E 01. Prior chemotherapy for prostate cancer,

- E 02. Less than 28 days elapsed from prior treatment with estramustine, radiotherapy
or surgery to the time of randomization. Participants on biphosphonates prior to study
entry.

- E 03. Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to >30% of
bone marrow.

- E 04. Adverse events (excluding alopecia and those listed in the specific exclusion
criteria) from any prior anticancer therapy of grade >1(National Cancer Institute
Common Terminology Criteria [NCI CTCAE] v4.03) at the time of randomization.

- E 05. Less than 18 years (or country's legal age of majority if the legal age is >18
years).

- E 06. Eastern Cooperative Oncology Group (ECOG) performance status >2.

- E 07. History of brain metastases, uncontrolled spinal cord compression, or
carcinomatous meningitis or new evidence of brain or leptomeningeal disease.

- E 08. Prior malignancy.

- E 09. Participation in another clinical trial and any concurrent treatment with any
investigational drug within 30 days prior to randomization.

- E 10. Any of the following within 6 months prior to study enrollment: myocardial
infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft,
New York Heart Association (NYHA) class III or IV congestive heart failure, stroke or
transient ischemic attack.

- E 11. Any of the following within 3 months prior to randomization: treatment resistant
peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory
bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled
thromboembolic event.

- E 12. Acquired immunodeficiency syndrome (AIDS-related illnesses) or known HIV disease
requiring antiretroviral treatment.

- E 13. Any severe acute or chronic medical condition which could impair the ability of
the participant to participate to the study or interfere with interpretation of study
results, or participants unable to comply with the study procedures.

- E 14. Absence of signed and dated Institutional Review Board (IRB)-approved
participant informed consent form prior to enrollment into the study.

- E 15. Participants with reproductive potential who did not agree to use accepted and
effective method of contraception during the study treatment period.

- E 16. History of hypersensitivity to docetaxel, or polysorbate 80.

- E 17. Inadequate organ and bone marrow function

- E 18. Contraindications to the use of corticosteroid treatment.

- E 19. Symptomatic peripheral neuropathy grade >2 (National Cancer Institute Common
Terminology Criteria [NCI CTCAE] v.4.03).

The above information was not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Investigational Site Number 036016 - Bankstown
Recruitment hospital [2] 0 0
Investigational Site Number 036008 - Camperdown
Recruitment hospital [3] 0 0
Investigational Site Number 036015 - Coffs Harbour
Recruitment hospital [4] 0 0
Investigational Site Number 036001 - Concord
Recruitment hospital [5] 0 0
Investigational Site Number 036017 - Fitzroy
Recruitment hospital [6] 0 0
Investigational Site Number 036003 - Herston
Recruitment hospital [7] 0 0
Investigational Site Number 036010 - Hornsby
Recruitment hospital [8] 0 0
Investigational Site Number 036012 - Kurralta Park
Recruitment hospital [9] 0 0
Investigational Site Number 036002 - Parkville
Recruitment hospital [10] 0 0
Investigational Site Number 036009 - South Brisbane
Recruitment hospital [11] 0 0
Investigational Site Number 036011 - Subiaco
Recruitment hospital [12] 0 0
Investigational Site Number 036013 - Wodonga
Recruitment postcode(s) [1] 0 0
2200 - Bankstown
Recruitment postcode(s) [2] 0 0
2050 - Camperdown
Recruitment postcode(s) [3] 0 0
2450 - Coffs Harbour
Recruitment postcode(s) [4] 0 0
2137 - Concord
Recruitment postcode(s) [5] 0 0
3065 - Fitzroy
Recruitment postcode(s) [6] 0 0
4029 - Herston
Recruitment postcode(s) [7] 0 0
2077 - Hornsby
Recruitment postcode(s) [8] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [9] 0 0
3050 - Parkville
Recruitment postcode(s) [10] 0 0
4101 - South Brisbane
Recruitment postcode(s) [11] 0 0
6008 - Subiaco
Recruitment postcode(s) [12] 0 0
3690 - Wodonga
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Kentucky
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Nebraska
Country [15] 0 0
United States of America
State/province [15] 0 0
New Jersey
Country [16] 0 0
United States of America
State/province [16] 0 0
New Mexico
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Rhode Island
Country [21] 0 0
United States of America
State/province [21] 0 0
South Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Tennessee
Country [23] 0 0
Belarus
State/province [23] 0 0
Minsk
Country [24] 0 0
Belarus
State/province [24] 0 0
Vitebsk
Country [25] 0 0
Brazil
State/province [25] 0 0
Passo Fundo
Country [26] 0 0
Brazil
State/province [26] 0 0
Porto Alegre
Country [27] 0 0
Brazil
State/province [27] 0 0
Rio De Janeiro
Country [28] 0 0
Brazil
State/province [28] 0 0
Sao Jose Do Rio Preto
Country [29] 0 0
Brazil
State/province [29] 0 0
Sao Paulo
Country [30] 0 0
Brazil
State/province [30] 0 0
Uberlandia
Country [31] 0 0
Canada
State/province [31] 0 0
London
Country [32] 0 0
Canada
State/province [32] 0 0
Mississauga
Country [33] 0 0
Canada
State/province [33] 0 0
Moncton
Country [34] 0 0
Canada
State/province [34] 0 0
Montreal
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
Canada
State/province [36] 0 0
Toronto
Country [37] 0 0
China
State/province [37] 0 0
Beijing
Country [38] 0 0
China
State/province [38] 0 0
Shanghai
Country [39] 0 0
Czechia
State/province [39] 0 0
Brno
Country [40] 0 0
Czechia
State/province [40] 0 0
Novy Jicin
Country [41] 0 0
Czechia
State/province [41] 0 0
Olomouc
Country [42] 0 0
Czechia
State/province [42] 0 0
Praha 2
Country [43] 0 0
Denmark
State/province [43] 0 0
Herlev
Country [44] 0 0
Denmark
State/province [44] 0 0
København Ø
Country [45] 0 0
Denmark
State/province [45] 0 0
Odense C
Country [46] 0 0
Denmark
State/province [46] 0 0
Ålborg
Country [47] 0 0
Finland
State/province [47] 0 0
Helsinki
Country [48] 0 0
Finland
State/province [48] 0 0
Kuopio
Country [49] 0 0
Finland
State/province [49] 0 0
Turku
Country [50] 0 0
France
State/province [50] 0 0
Besancon Cedex
Country [51] 0 0
France
State/province [51] 0 0
Bordeaux Cedex
Country [52] 0 0
France
State/province [52] 0 0
Caen Cedex 05
Country [53] 0 0
France
State/province [53] 0 0
Lyon
Country [54] 0 0
France
State/province [54] 0 0
Paris Cedex 05
Country [55] 0 0
France
State/province [55] 0 0
Paris Cedex 10
Country [56] 0 0
France
State/province [56] 0 0
Paris Cedex 15
Country [57] 0 0
France
State/province [57] 0 0
Poitiers Cedex
Country [58] 0 0
France
State/province [58] 0 0
Suresnes
Country [59] 0 0
France
State/province [59] 0 0
Villejuif
Country [60] 0 0
Germany
State/province [60] 0 0
Aachen
Country [61] 0 0
Germany
State/province [61] 0 0
Berlin
Country [62] 0 0
Germany
State/province [62] 0 0
Düsseldorf
Country [63] 0 0
Germany
State/province [63] 0 0
Erlangen
Country [64] 0 0
Germany
State/province [64] 0 0
Homburg
Country [65] 0 0
Germany
State/province [65] 0 0
München
Country [66] 0 0
Israel
State/province [66] 0 0
Kfar Saba
Country [67] 0 0
Israel
State/province [67] 0 0
Petah-Tikva
Country [68] 0 0
Israel
State/province [68] 0 0
Tel Aviv
Country [69] 0 0
Italy
State/province [69] 0 0
Arezzo
Country [70] 0 0
Italy
State/province [70] 0 0
Bari
Country [71] 0 0
Italy
State/province [71] 0 0
Orbassano
Country [72] 0 0
Italy
State/province [72] 0 0
Roma
Country [73] 0 0
Italy
State/province [73] 0 0
Trento
Country [74] 0 0
Japan
State/province [74] 0 0
Bunkyo-Ku
Country [75] 0 0
Japan
State/province [75] 0 0
Chiba-Shi
Country [76] 0 0
Japan
State/province [76] 0 0
Kashiwa-Shi
Country [77] 0 0
Japan
State/province [77] 0 0
Koto-Ku
Country [78] 0 0
Japan
State/province [78] 0 0
Osaka Sayama-Shi
Country [79] 0 0
Japan
State/province [79] 0 0
Osaka-Shi
Country [80] 0 0
Mexico
State/province [80] 0 0
Acapulco
Country [81] 0 0
Mexico
State/province [81] 0 0
Aguascalientes
Country [82] 0 0
Mexico
State/province [82] 0 0
D.f.
Country [83] 0 0
Mexico
State/province [83] 0 0
Guadalajara
Country [84] 0 0
Mexico
State/province [84] 0 0
Merida
Country [85] 0 0
Mexico
State/province [85] 0 0
Queretaro
Country [86] 0 0
Mexico
State/province [86] 0 0
San Luis Potosi
Country [87] 0 0
Mexico
State/province [87] 0 0
Zapopan
Country [88] 0 0
Peru
State/province [88] 0 0
Lima
Country [89] 0 0
Poland
State/province [89] 0 0
Bydgoszcz
Country [90] 0 0
Poland
State/province [90] 0 0
Gdansk
Country [91] 0 0
Poland
State/province [91] 0 0
Koscierzyna
Country [92] 0 0
Poland
State/province [92] 0 0
Lodz
Country [93] 0 0
Poland
State/province [93] 0 0
Poznan
Country [94] 0 0
Portugal
State/province [94] 0 0
Coimbra
Country [95] 0 0
Portugal
State/province [95] 0 0
Lisboa
Country [96] 0 0
Portugal
State/province [96] 0 0
Porto
Country [97] 0 0
Romania
State/province [97] 0 0
Baia Mare
Country [98] 0 0
Romania
State/province [98] 0 0
Bucharest
Country [99] 0 0
Romania
State/province [99] 0 0
Bucuresti
Country [100] 0 0
Romania
State/province [100] 0 0
Cluj Napoca
Country [101] 0 0
Romania
State/province [101] 0 0
Hunedoara
Country [102] 0 0
Russian Federation
State/province [102] 0 0
Ekaterinburg
Country [103] 0 0
Russian Federation
State/province [103] 0 0
Moscow
Country [104] 0 0
Russian Federation
State/province [104] 0 0
Omsk
Country [105] 0 0
Russian Federation
State/province [105] 0 0
Pyatigorsk
Country [106] 0 0
Russian Federation
State/province [106] 0 0
Ryazan
Country [107] 0 0
Russian Federation
State/province [107] 0 0
St-Petersburg
Country [108] 0 0
Russian Federation
State/province [108] 0 0
Tomsk
Country [109] 0 0
Russian Federation
State/province [109] 0 0
Yaroslavl
Country [110] 0 0
Spain
State/province [110] 0 0
Barcelona
Country [111] 0 0
Spain
State/province [111] 0 0
Hospitalet De Llobregat
Country [112] 0 0
Spain
State/province [112] 0 0
Madrid
Country [113] 0 0
Spain
State/province [113] 0 0
Santiago De Compostela
Country [114] 0 0
Sweden
State/province [114] 0 0
Malmö
Country [115] 0 0
Sweden
State/province [115] 0 0
Stockholm
Country [116] 0 0
Sweden
State/province [116] 0 0
Uppsala
Country [117] 0 0
Taiwan
State/province [117] 0 0
Kaohsiung
Country [118] 0 0
Taiwan
State/province [118] 0 0
Taichung
Country [119] 0 0
Taiwan
State/province [119] 0 0
Taipei
Country [120] 0 0
Taiwan
State/province [120] 0 0
Tao-Yuan
Country [121] 0 0
Turkey
State/province [121] 0 0
Ankara
Country [122] 0 0
Turkey
State/province [122] 0 0
Istanbul
Country [123] 0 0
Ukraine
State/province [123] 0 0
Cherkasy
Country [124] 0 0
Ukraine
State/province [124] 0 0
Dnipropetrovsk
Country [125] 0 0
Ukraine
State/province [125] 0 0
Donetsk
Country [126] 0 0
Ukraine
State/province [126] 0 0
Ivano-Frankivsk
Country [127] 0 0
Ukraine
State/province [127] 0 0
Kharkov
Country [128] 0 0
Ukraine
State/province [128] 0 0
Kyiv
Country [129] 0 0
Ukraine
State/province [129] 0 0
Lutsk
Country [130] 0 0
Ukraine
State/province [130] 0 0
Uzhgorod
Country [131] 0 0
Ukraine
State/province [131] 0 0
Zaporizhzhya

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Sanofi
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Primary Objective:

- To demonstrate the superiority of cabazitaxel plus prednisone at 25 mg/m^2 (Arm A) or 20
mg/m^2 (Arm B) versus docetaxel plus prednisone (Arm C) in term of overall survival (OS)
in participants with metastatic castration resistant prostate cancer (mCRPC) and not
previously treated with chemotherapy.

Secondary Objectives:

- To evaluate safety in the 3 treatment arms.

- To compare efficacy of cabazitaxel at 20 mg/m^2 and 25 mg/m^2 to docetaxel for:

- Progression Free Survival (PFS) (RECIST 1.1)

- Tumor progression free survival (RECIST 1.1)

- Tumor response in participants with measurable disease (RECIST 1.1),

- PSA response

- PSA-Progression free survival (PSA-PFS).

- Pain response in participants with stable pain at baseline

- Pain progression free survival

- Time to occurrence of any skeletal related events (SRE)

- To compare Health-Related Quality of Life (HRQL).

- To assess the pharmacokinetics and pharmacogenomics of cabazitaxel.
Trial website
https://clinicaltrials.gov/show/NCT01308567
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Sciences & Operations
Address 0 0
Sanofi
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries